Feature

Feature

Pharmaceutical companies are increasingly using big data techniques to improve outcomes, streamline the drug clinical pipeline and gain insight into new therapies. But real innovation may change how drug developers, payers, and providers interact with patient data.

A group of experts recently commented on President Trump's new law addressing the opioid crisis that received strong bipartisan support, which provides multiple measures to more aggressively address what has become a steady and growing epidemic over decades.

The Trump Administration recently released a 100-day progress report on the American Patients First Blueprint, touting its accomplishments to date. Our experts analyzed what has really changed and the likely impact on the pharmaceutical market.

Some big companies are ditching traditional methods and taking a more hands-on approach to employee health in order to cut into rising costs. Could their efforts to alter the status quo wind up transforming the delivery of medical care?

Studies have shown success with hepatitis C-positive kidney transplantation in patients with end-stage renal disease followed by treatment with direct-acting antivirals to cure the infection. Experts discuss why this approach is not only beneficial for patients, but also cost-effective for payers.

Consumers will now have the ability to purchase short-term, limited-duration insurance policies for more extended periods of time. Experts weigh in on the potential impact of increased access to less comprehensive plans.

A report is coming on drug price increases that are unsupported by evidence. How should stakeholders prepare, and when does it make sense for drugmakers to push back?

Payers are implementing a new strategy to counter the effects of drug manufacturer patient assistance programs. We take a closer look at these emerging copay accumulator programs and their potential ripple effect. 

Gene therapy is a transformational treatment for some patients to potentially cure or prevent rare diseases. But questions still remain about how these drugs should be priced and who will pay for them.

Mary Barton, MD, MPP, vice president of performance at NCQA, explains how the process is becoming more aligned with real-world practice, what specific initiatives are being introduced or changed, and what organizations can start going now to get ready.